Almirall acquires US medical dermatology portfolio from Allergan
Almirall, S.A. (ALM) has announced the acquisition of a portfolio of five products from Allergan’s Medical Dermatology unit in the United States for $500...
UDG Healthcare acquire Create NYC and SmartAnalyst
UDG Healthcare plc, an international healthcare services provider, is pleased to announce the acquisition of Create NYC, a New York-based disruptive creative communications agency...
Laekna acquires worldwide rights to two oncology assets
Laekna Inc., a biotechnology company headquartered in Shanghai, announced the signing of an agreement with Novartis Pharma for exclusive global rights to develop and...
LEO Pharma to acquire Bayer’s dermatology unit
LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription...
AstraZeneca sells rights for Atacand to Cheplapharm
AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe...
NanoGenics acquired to advance gene therapy
The Scottish Biotech company Ryboquin, announces the acquisition of Nanogenic Solutions, to form a new product and platform company, Nanogenics Limited. The combined company,...
EUSA Pharma announce acquisition of SYLVANT® from Janssen
EUSA Pharma acquires SYLVANT from Janssen for $115 million
BioIVT acquires Optivia Biotechnology
BioIVT, a provider of research models and services for drug development, has announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its...
Sanofi and Advent finalise negotiations for the acquisition of Zentiva
Sanofi and Advent International (Advent) have finished negotiations for the acquisition of Zentiva - Sanofi's European generics business. Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion...
Takeda ups bid to $65 billion in negotiations to buy Shire
Takeda has increased offer to buy Shire for a mix of stock and cash worth ~$65 billion
Latest articles
IMBRUVICA® misses primary endpoint in pancreatic cancer trial
AbbVie have released an update on the RESOLVE trial of IMBRUVICA® in combination with chemotherapy agents in metastatic pancreatic cancer. AbbVie, a research-based global biopharmaceutical company,...
Star Europe’s Amsterdam office off to positive start
Star Europe has reported good feedback in the Netherlands since opening its Amsterdam office in November. Supported by established resources and infrastructure, the team at...
EC approves Vertex’s ORKAMBI® for cystic fibrosis patients
Vertex Pharmaceuticals announces that the European Commission has granted approval of the label extension for ORKAMBI® for cystic fibrosis patients. The European Commission has granted approval...